Human umbilical cord matrix stem cells

Preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease

Mark L. Weiss, Satish Medicetty, Amber R. Bledsoe, Raja Shekar Rachakatla, Michael Choi, Shosh Merchav, Yongquan Luo, Mahendra S. Rao, Gopalrao V Velagaleti, Deryl Troyer

Research output: Contribution to journalArticle

531 Citations (Scopus)

Abstract

The umbilical cord contains an inexhaustible, noncontroversial source of stem cells for therapy. In the U.S., stem cells found in the umbilical cord are routinely placed into biohazardous waste after birth. Here, stem cells derived from human umbilical cord Wharton's Jelly, called umbilical cord matrix stem (UCMS) cells, are characterized. UCMS cells have several properties that make them of interest as a source of cells for therapeutic use. For example, they 1) can be isolated in large numbers, 2) are negative for CD34 and CD45, 3) grow robustly and can be frozen/thawed, 4) can be clonally expanded, and 5) can easily be engineered to express exogenous proteins. UCMS cells have genetic and surface markers of mesenchymal stem cells (positive for CD10, CD13, CD29, CD44, and CD90 and negative for CD14, CD33, CD56, CD31, CD34, CD45, and HLA-DR) and appear to be stable in terms of their surface marker expression in early passage (passages 4-8). Unlike traditional mesenchymal stem cells derived from adult bone marrow stromal cells, small populations of UCMS cells express endoglin (SH2, CD105) and CD49e at passage 8. UCMS cells express growth factors and angiogenic factors, suggesting that they may be used to treat neurodegenerative disease. To test the therapeutic value of UCMS cells, undifferentiated human UCMS cells were transplanted into the brains of hemiparkinsonian rats that were not immune-suppressed. UCMS cells ameliorated apomorphine-induced rotations in the pilot test. UCMS cells transplanted into normal rats did not produce brain tumors, rotational behavior, or a frank host immune rejection response. In summary, the umbilical cord matrix appears to be a rich, noncontroversial, and inexhaustible source of primitive mesenchymal stem cells.

Original languageEnglish (US)
Pages (from-to)781-792
Number of pages12
JournalStem Cells
Volume24
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Umbilical Cord
Parkinson Disease
Rodentia
Stem Cells
Transplantation
Mesenchymal Stromal Cells
Wharton Jelly
Apomorphine
Angiogenesis Inducing Agents
HLA-DR Antigens
Therapeutic Uses
Cell- and Tissue-Based Therapy
Genetic Markers
Brain Neoplasms
Neurodegenerative Diseases
Intercellular Signaling Peptides and Proteins

Keywords

  • Flow cytometry
  • In vitro expansion Noncontroversial source of stem cells
  • Regenerative medicine
  • Wharton's jelly

ASJC Scopus subject areas

  • Cell Biology

Cite this

Weiss, M. L., Medicetty, S., Bledsoe, A. R., Rachakatla, R. S., Choi, M., Merchav, S., ... Troyer, D. (2006). Human umbilical cord matrix stem cells: Preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells, 24(3), 781-792. https://doi.org/10.1634/stemcells.2005-0330

Human umbilical cord matrix stem cells : Preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. / Weiss, Mark L.; Medicetty, Satish; Bledsoe, Amber R.; Rachakatla, Raja Shekar; Choi, Michael; Merchav, Shosh; Luo, Yongquan; Rao, Mahendra S.; Velagaleti, Gopalrao V; Troyer, Deryl.

In: Stem Cells, Vol. 24, No. 3, 03.2006, p. 781-792.

Research output: Contribution to journalArticle

Weiss, ML, Medicetty, S, Bledsoe, AR, Rachakatla, RS, Choi, M, Merchav, S, Luo, Y, Rao, MS, Velagaleti, GV & Troyer, D 2006, 'Human umbilical cord matrix stem cells: Preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease', Stem Cells, vol. 24, no. 3, pp. 781-792. https://doi.org/10.1634/stemcells.2005-0330
Weiss, Mark L. ; Medicetty, Satish ; Bledsoe, Amber R. ; Rachakatla, Raja Shekar ; Choi, Michael ; Merchav, Shosh ; Luo, Yongquan ; Rao, Mahendra S. ; Velagaleti, Gopalrao V ; Troyer, Deryl. / Human umbilical cord matrix stem cells : Preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. In: Stem Cells. 2006 ; Vol. 24, No. 3. pp. 781-792.
@article{63aebe171ec34768941d7f52385d5b7c,
title = "Human umbilical cord matrix stem cells: Preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease",
abstract = "The umbilical cord contains an inexhaustible, noncontroversial source of stem cells for therapy. In the U.S., stem cells found in the umbilical cord are routinely placed into biohazardous waste after birth. Here, stem cells derived from human umbilical cord Wharton's Jelly, called umbilical cord matrix stem (UCMS) cells, are characterized. UCMS cells have several properties that make them of interest as a source of cells for therapeutic use. For example, they 1) can be isolated in large numbers, 2) are negative for CD34 and CD45, 3) grow robustly and can be frozen/thawed, 4) can be clonally expanded, and 5) can easily be engineered to express exogenous proteins. UCMS cells have genetic and surface markers of mesenchymal stem cells (positive for CD10, CD13, CD29, CD44, and CD90 and negative for CD14, CD33, CD56, CD31, CD34, CD45, and HLA-DR) and appear to be stable in terms of their surface marker expression in early passage (passages 4-8). Unlike traditional mesenchymal stem cells derived from adult bone marrow stromal cells, small populations of UCMS cells express endoglin (SH2, CD105) and CD49e at passage 8. UCMS cells express growth factors and angiogenic factors, suggesting that they may be used to treat neurodegenerative disease. To test the therapeutic value of UCMS cells, undifferentiated human UCMS cells were transplanted into the brains of hemiparkinsonian rats that were not immune-suppressed. UCMS cells ameliorated apomorphine-induced rotations in the pilot test. UCMS cells transplanted into normal rats did not produce brain tumors, rotational behavior, or a frank host immune rejection response. In summary, the umbilical cord matrix appears to be a rich, noncontroversial, and inexhaustible source of primitive mesenchymal stem cells.",
keywords = "Flow cytometry, In vitro expansion Noncontroversial source of stem cells, Regenerative medicine, Wharton's jelly",
author = "Weiss, {Mark L.} and Satish Medicetty and Bledsoe, {Amber R.} and Rachakatla, {Raja Shekar} and Michael Choi and Shosh Merchav and Yongquan Luo and Rao, {Mahendra S.} and Velagaleti, {Gopalrao V} and Deryl Troyer",
year = "2006",
month = "3",
doi = "10.1634/stemcells.2005-0330",
language = "English (US)",
volume = "24",
pages = "781--792",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - Human umbilical cord matrix stem cells

T2 - Preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease

AU - Weiss, Mark L.

AU - Medicetty, Satish

AU - Bledsoe, Amber R.

AU - Rachakatla, Raja Shekar

AU - Choi, Michael

AU - Merchav, Shosh

AU - Luo, Yongquan

AU - Rao, Mahendra S.

AU - Velagaleti, Gopalrao V

AU - Troyer, Deryl

PY - 2006/3

Y1 - 2006/3

N2 - The umbilical cord contains an inexhaustible, noncontroversial source of stem cells for therapy. In the U.S., stem cells found in the umbilical cord are routinely placed into biohazardous waste after birth. Here, stem cells derived from human umbilical cord Wharton's Jelly, called umbilical cord matrix stem (UCMS) cells, are characterized. UCMS cells have several properties that make them of interest as a source of cells for therapeutic use. For example, they 1) can be isolated in large numbers, 2) are negative for CD34 and CD45, 3) grow robustly and can be frozen/thawed, 4) can be clonally expanded, and 5) can easily be engineered to express exogenous proteins. UCMS cells have genetic and surface markers of mesenchymal stem cells (positive for CD10, CD13, CD29, CD44, and CD90 and negative for CD14, CD33, CD56, CD31, CD34, CD45, and HLA-DR) and appear to be stable in terms of their surface marker expression in early passage (passages 4-8). Unlike traditional mesenchymal stem cells derived from adult bone marrow stromal cells, small populations of UCMS cells express endoglin (SH2, CD105) and CD49e at passage 8. UCMS cells express growth factors and angiogenic factors, suggesting that they may be used to treat neurodegenerative disease. To test the therapeutic value of UCMS cells, undifferentiated human UCMS cells were transplanted into the brains of hemiparkinsonian rats that were not immune-suppressed. UCMS cells ameliorated apomorphine-induced rotations in the pilot test. UCMS cells transplanted into normal rats did not produce brain tumors, rotational behavior, or a frank host immune rejection response. In summary, the umbilical cord matrix appears to be a rich, noncontroversial, and inexhaustible source of primitive mesenchymal stem cells.

AB - The umbilical cord contains an inexhaustible, noncontroversial source of stem cells for therapy. In the U.S., stem cells found in the umbilical cord are routinely placed into biohazardous waste after birth. Here, stem cells derived from human umbilical cord Wharton's Jelly, called umbilical cord matrix stem (UCMS) cells, are characterized. UCMS cells have several properties that make them of interest as a source of cells for therapeutic use. For example, they 1) can be isolated in large numbers, 2) are negative for CD34 and CD45, 3) grow robustly and can be frozen/thawed, 4) can be clonally expanded, and 5) can easily be engineered to express exogenous proteins. UCMS cells have genetic and surface markers of mesenchymal stem cells (positive for CD10, CD13, CD29, CD44, and CD90 and negative for CD14, CD33, CD56, CD31, CD34, CD45, and HLA-DR) and appear to be stable in terms of their surface marker expression in early passage (passages 4-8). Unlike traditional mesenchymal stem cells derived from adult bone marrow stromal cells, small populations of UCMS cells express endoglin (SH2, CD105) and CD49e at passage 8. UCMS cells express growth factors and angiogenic factors, suggesting that they may be used to treat neurodegenerative disease. To test the therapeutic value of UCMS cells, undifferentiated human UCMS cells were transplanted into the brains of hemiparkinsonian rats that were not immune-suppressed. UCMS cells ameliorated apomorphine-induced rotations in the pilot test. UCMS cells transplanted into normal rats did not produce brain tumors, rotational behavior, or a frank host immune rejection response. In summary, the umbilical cord matrix appears to be a rich, noncontroversial, and inexhaustible source of primitive mesenchymal stem cells.

KW - Flow cytometry

KW - In vitro expansion Noncontroversial source of stem cells

KW - Regenerative medicine

KW - Wharton's jelly

UR - http://www.scopus.com/inward/record.url?scp=33744973827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744973827&partnerID=8YFLogxK

U2 - 10.1634/stemcells.2005-0330

DO - 10.1634/stemcells.2005-0330

M3 - Article

VL - 24

SP - 781

EP - 792

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 3

ER -